These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 36476658)
1. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma. Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658 [TBL] [Abstract][Full Text] [Related]
2. Low grade serous ovarian cancer - A rare disease with increasing therapeutic options. Zwimpfer TA; Tal O; Geissler F; Coelho R; Rimmer N; Jacob F; Heinzelmann-Schwarz V Cancer Treat Rev; 2023 Jan; 112():102497. PubMed ID: 36525716 [TBL] [Abstract][Full Text] [Related]
3. A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma. Voutsadakis IA Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():172-178. PubMed ID: 33246201 [TBL] [Abstract][Full Text] [Related]
4. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350 [TBL] [Abstract][Full Text] [Related]
5. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma. Hollis RL; Elliott R; Dawson JC; Ilenkovan N; Matthews RM; Stillie LJ; Oswald AJ; Kim H; Llaurado Fernandez M; Churchman M; Porter JM; Roxburgh P; Unciti-Broceta A; Gershenson DM; Herrington CS; Carey MS; Carragher NO; Gourley C Gynecol Oncol; 2024 Jul; 186():42-52. PubMed ID: 38582027 [TBL] [Abstract][Full Text] [Related]
6. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability. Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310 [TBL] [Abstract][Full Text] [Related]
7. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum. Grisham RN; Chui MH Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920 [TBL] [Abstract][Full Text] [Related]
8. Advances in precision therapy of low-grade serous ovarian cancer: A review. Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365 [TBL] [Abstract][Full Text] [Related]
9. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition. Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031 [TBL] [Abstract][Full Text] [Related]
11. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906 [TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer. Mert I; Chhina J; Allo G; Dai J; Seward S; Carey MS; Llaurado M; Giri S; Rattan R; Munkarah AR Gynecol Oncol; 2017 Aug; 146(2):319-326. PubMed ID: 28545687 [TBL] [Abstract][Full Text] [Related]
13. Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883 [TBL] [Abstract][Full Text] [Related]
14. Low-grade serous ovarian carcinoma: A comprehensive literature review. Goulding EA; Simcock B; McLachlan J; van der Griend R; Sykes P Aust N Z J Obstet Gynaecol; 2020 Feb; 60(1):27-33. PubMed ID: 31849044 [TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. McNamara B; Demirkiran C; Hartwich TMP; Bellone S; Manavella D; Mutlu L; Greenman M; Zipponi M; Yang-Hartwich Y; Yang K; Ratner E; Schwartz PE; Coma S; Pachter JA; Santin AD Gynecol Oncol; 2024 Apr; 183():133-140. PubMed ID: 38493021 [TBL] [Abstract][Full Text] [Related]
16. Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers. Azzalini E; Stanta G; Canzonieri V; Bonin S Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894756 [TBL] [Abstract][Full Text] [Related]
17. The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis. Hendrikse CSE; Theelen PMM; van der Ploeg P; Westgeest HM; Boere IA; Thijs AMJ; Ottevanger PB; van de Stolpe A; Lambrechts S; Bekkers RLM; Piek JMJ Gynecol Oncol; 2023 Apr; 171():83-94. PubMed ID: 36841040 [TBL] [Abstract][Full Text] [Related]
18. High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. Pishas KI; Cowley KJ; Llaurado-Fernandez M; Kim H; Luu J; Vary R; Bowden NA; Campbell IG; Carey MS; Simpson KJ; Cheasley D Sci Data; 2024 Sep; 11(1):1024. PubMed ID: 39300112 [TBL] [Abstract][Full Text] [Related]
19. Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a Colombo I; Garg S; Danesh A; Bruce J; Shaw P; Tan Q; Quevedo R; Braunstein M; Oza AM; Pugh T; Lheureux S Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31836588 [TBL] [Abstract][Full Text] [Related]
20. [Cytopathological characterization of ascites for the diagnosis of serous ovarian carcinoma]. Chang YH; Zou BQ; Cai Y; Yang SD; Zhang Y; Liang JB; Li C Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):424-432. PubMed ID: 37188628 [No Abstract] [Full Text] [Related] [Next] [New Search]